The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Venetoclax-based therapies for acute myeloid leukemia
Open accessAbstract
The prognosis of adult acute myeloid leukemia (AML) remains poor, with the long-term survival rate less than 50%. However, the current paradigms of treatment are changing through a better understanding of the disease genetics and pathophysiology. Since 2017, eight new drugs have been approved by the U.S. Food and Drug Administration for the treatment of AML, including the FLT3 inhibitors midostaurin and gilteritinib, the IDH inhibitors ivosidenib and enasidenib, the anti-CD33 monoclonal antibody gemtuzumab ozogamicin, liposomal daunorubicin and cytarabine, the hedgehog pathway inhibitor glasdegib and the BCL-2 inhibitor venetoclax. Preclinical data demonstrated the anti-leukemic efficacy of venetoclax in AML and its synergy when combined with hypomethylating agents or chemotherapy agents. Clinical trials have demonstrated the clinical benefit of venetoclax-based therapies in newly diagnosed AML, leading to the recent FDA approval of venetoclax in combination with hypomethylating agents or low-dose cytarabine for older adults with newly diagnosed AML. Herein, we focus on the role of single-agent BCL-2 inhibition in AML and review the clinical studies of venetoclax-based combination regimens and the evolving mechanisms of resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour, J. F., Kipps, T. J., Eichhorst, B., Hillmen, P., D’Rozario, J., Assouline, S., Owen, C., Gerecitano, J., Robak, T., De la Serna, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713976 · Cited by 940
Mechanisms of Action of Bcl-2 Family Proteins
Shamas-Din, A., Kale, J., Leber, B., & Andrews, D. W. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a008714 · Cited by 705
Burnett, A. K., Milligan, D., Prentice, A. G., Goldstone, A. H., McMullin, M. F., Hills, R. K., & Wheatley, K. (2007) · Cancer · doi:10.1002/cncr.22496 · Cited by 619
Caenepeel, S., Brown, S. P., Belmontes, B., Moody, G., Keegan, K. S., Chui, D., Whittington, D. A., Huang, X., Poppe, L., Cheng, A. C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0387 · Cited by 432
Quivoron, C., David, M., Straley, K., Travins, J., Kim, H., Chen, Y., Zhu, D., Saada, V., Bawa, O., Opolon, P., et al. (2014) · Blood · doi:10.1182/blood.v124.21.3735.3735 · Cited by 19
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
Sasaki, K., Ravandi, F., Kadia, T. M., DiNardo, C. D., Short, N. J., Borthakur, G., Jabbour, E., & Kantarjian, H. M. (2021) · Cancer · doi:10.1002/cncr.33458 · Cited by 276
Self-citationNew directions for emerging therapies in acute myeloid leukemia: the next chapter
Daver, N., Wei, A. H., Pollyea, D. A., Fathi, A. T., Vyas, P., & DiNardo, C. D. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00376-1 · Cited by 159
Self-citationKhan, S., Cao, L., Wiegand, J., Zhang, P., Zajac-Kaye, M., Kaye, F. J., Zheng, G., & Zhou, D. (2024) · Cells · doi:10.3390/cells13060528 · Cited by 34
Huang, S., Li, C., Zhang, X., Pan, J., Li, F., Lv, Y., Huang, J., Ling, Q., Ye, W., Mao, S., et al. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12742 · Cited by 7
Metadata
- Authors
- Guerra, V. A., DiNardo, C., & Konopleva, M.
- Venue
- Best Practice & Research Clinical Haematology
- Publisher
- Elsevier BV
- Published
- 2019-06
- Volume
- 32
- Issue
- 2
- Pages
- 145-153
- ISSN
- 1521-6926 (ISSN-L)
- OpenAlex
- W2945338000
- Cited by
- 174
- References
- 7
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Venetoclax-based therapies for acute myeloid leukemia. https://app.cochat.ai/papers/10.1016/j.beha.2019.05.008
- The paper
- Guerra, V. A., DiNardo, C., & Konopleva, M. (2019). Venetoclax-based therapies for acute myeloid leukemia. Best Practice & Research Clinical Haematology. https://doi.org/10.1016/j.beha.2019.05.008
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.